{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T19:06:28Z","timestamp":1724699188301},"reference-count":11,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,6,15]]},"DOI":"10.1001\/jama.2021.7275","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T15:00:52Z","timestamp":1623769252000},"page":"2346","source":"Crossref","is-referenced-by-count":3,"title":["Acute Treatment for Migraine"],"prefix":"10.1001","volume":"325","author":[{"given":"Rebecca","family":"Burch","sequence":"first","affiliation":[{"name":"Graham Headache Center, Brigham and Women's Hospital Department of Neurology, Harvard Medical School, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Rayhill","sequence":"additional","affiliation":[{"name":"Department of Neurology, University at Buffalo, State University of New York, Buffalo, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"jed210036r1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1526-4610.2002.0420s1003.x","article-title":"What do patients with migraine want from acute migraine treatment?","volume":"42","author":"Lipton","year":"2002","journal-title":"Headache"},{"issue":"1","key":"jed210036r2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","article-title":"The American Headache Society position statement on integrating new migraine treatments into clinical practice.","volume":"59","author":"American Headache Society","year":"2019","journal-title":"Headache"},{"issue":"10","key":"jed210036r3","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/head.2016.56.issue-10","article-title":"Predicting inadequate response to acute migraine medication: results from the American Migraine Prevalence and Prevention (AMPP) study.","volume":"56","author":"Lipton","year":"2016","journal-title":"Headache"},{"issue":"4","key":"jed210036r4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: epidemiology, burden, and comorbidity.","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol Clin"},{"issue":"4","key":"jed210036r5","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/head.v60.4","article-title":"Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II.","volume":"60","author":"Dodick","year":"2020","journal-title":"Headache"},{"issue":"1","key":"jed210036r6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10194-020-01088-4","article-title":"Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.","volume":"21","author":"Lipton","year":"2020","journal-title":"J Headache Pain"},{"key":"jed210036r7","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.7939","article-title":"Acute treatments for episodic migraine in adults: a systematic review and meta-analysis.","author":"VanderPluym","year":"2021","journal-title":"JAMA"},{"key":"jed210036r8","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.7665","article-title":"Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial.","author":"Winner","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"jed210036r9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/head.2014.54.issue-1","article-title":"Opioids in headache.","volume":"54","author":"Levin","year":"2014","journal-title":"Headache"},{"issue":"8","key":"jed210036r10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/hed.2008.48.issue-8","article-title":"Acute migraine medications and evolution from episodic to chronic migraine.","volume":"48","author":"Bigal","year":"2008","journal-title":"Headache"},{"issue":"10268","key":"jed210036r11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","article-title":"Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial.","volume":"397","author":"Croop","year":"2021","journal-title":"Lancet"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2781072\/jama_burch_2021_ed_210036_1623359441.3055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T22:34:22Z","timestamp":1699137262000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2781072"}},"subtitle":["Contemporary Treatments and Future Directions"],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":11,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,6,15]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.7275","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,15]]}}}